AU2005302618B2 - Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkaline agent for enhanced absorption - Google Patents

Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkaline agent for enhanced absorption Download PDF

Info

Publication number
AU2005302618B2
AU2005302618B2 AU2005302618A AU2005302618A AU2005302618B2 AU 2005302618 B2 AU2005302618 B2 AU 2005302618B2 AU 2005302618 A AU2005302618 A AU 2005302618A AU 2005302618 A AU2005302618 A AU 2005302618A AU 2005302618 B2 AU2005302618 B2 AU 2005302618B2
Authority
AU
Australia
Prior art keywords
composition
analgesic
antipyretic
acetaminophen
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005302618A
Other languages
English (en)
Other versions
AU2005302618A1 (en
Inventor
Atef Z. Boulos
Candice Y. Choi
Michael Corbo
Jatin Desai
Gerard P. Frunzi
Rahul R. Gandhi
Rong Liu
Xiaohong Qi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haleon CH SARL
Original Assignee
Haleon CH SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haleon CH SARL filed Critical Haleon CH SARL
Publication of AU2005302618A1 publication Critical patent/AU2005302618A1/en
Application granted granted Critical
Publication of AU2005302618B2 publication Critical patent/AU2005302618B2/en
Assigned to GSK Consumer Healthcare S.A. reassignment GSK Consumer Healthcare S.A. Request for Assignment Assignors: NOVARTIS AG
Assigned to GSK CONSUMER HEALTHCARE SARL reassignment GSK CONSUMER HEALTHCARE SARL Request to Amend Deed and Register Assignors: GSK Consumer Healthcare S.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005302618A 2004-10-28 2005-10-26 Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkaline agent for enhanced absorption Expired AU2005302618B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62281204P 2004-10-28 2004-10-28
US60/622,812 2004-10-28
PCT/US2005/038507 WO2006049978A1 (en) 2004-10-28 2005-10-26 Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkiline agent fr enhanced absorption

Publications (2)

Publication Number Publication Date
AU2005302618A1 AU2005302618A1 (en) 2006-05-11
AU2005302618B2 true AU2005302618B2 (en) 2009-10-22

Family

ID=35744599

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005302618A Expired AU2005302618B2 (en) 2004-10-28 2005-10-26 Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkaline agent for enhanced absorption

Country Status (17)

Country Link
US (1) US20070298096A1 (cg-RX-API-DMAC10.html)
EP (1) EP1807068B1 (cg-RX-API-DMAC10.html)
JP (1) JP2008518914A (cg-RX-API-DMAC10.html)
CN (1) CN101048155A (cg-RX-API-DMAC10.html)
AR (1) AR051145A1 (cg-RX-API-DMAC10.html)
AT (1) ATE460930T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005302618B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0520000A2 (cg-RX-API-DMAC10.html)
CA (1) CA2583517C (cg-RX-API-DMAC10.html)
DE (1) DE602005020048D1 (cg-RX-API-DMAC10.html)
MX (1) MX2007005121A (cg-RX-API-DMAC10.html)
NO (1) NO20072255L (cg-RX-API-DMAC10.html)
PE (1) PE20061125A1 (cg-RX-API-DMAC10.html)
PL (1) PL1807068T3 (cg-RX-API-DMAC10.html)
PT (1) PT1807068E (cg-RX-API-DMAC10.html)
RU (1) RU2398571C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006049978A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607085D0 (en) 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
CN100417385C (zh) * 2006-09-26 2008-09-10 林星 一种用于治疗外伤的外用制剂
GB0707489D0 (en) * 2007-04-18 2007-05-23 Renaissance Pharma Compounds
CN101596163B (zh) * 2008-06-06 2012-06-27 康美保宁(四川)制药有限公司 阿咖酚微丸制剂及其制备方法
GB0813929D0 (en) * 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
CN102861040B (zh) * 2012-08-02 2014-04-23 广东环球制药有限公司 含有阿司匹林、对乙酰氨基酚和咖啡因的药物组合物及其制备方法
CN102949401A (zh) * 2012-09-06 2013-03-06 广东九明制药有限公司 对乙酰氨基酚、乙酰水杨酸和咖啡因组合物及其制备工艺
US10124005B1 (en) * 2017-12-15 2018-11-13 Lisa Josette Myslinski Multisymptom migraine combination medication
CN110711197B (zh) * 2018-07-12 2023-11-24 北京恒润泰生医药科技有限公司 阿司匹林和对乙酰氨基酚的分子复合物加咖啡因,其制备,活性及应用
CN108853124A (zh) * 2018-08-15 2018-11-23 康美保宁(四川)制药有限公司 一种阿咖酚制剂及其制剂方法
GB202007670D0 (en) * 2020-05-22 2020-07-08 Glaxosmithkline Consumer Healthcare Holdings Us Llc Pharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
US5296241A (en) * 1991-04-03 1994-03-22 Brimberg Barnett J Therapeutic composition and method of using same for treatment of hangover
US6316025B1 (en) * 1997-03-05 2001-11-13 Smithkline Beecham Plc Swallow tablet comprising paracetamol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1182049A (en) * 1981-07-13 1985-02-05 Francis J. Sterbenz Apap antacid composition
JP3122748B2 (ja) * 1991-11-29 2001-01-09 ライオン株式会社 イブプロフェン含有解熱鎮痛剤
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
JPH06227995A (ja) * 1993-02-03 1994-08-16 Takeda Chem Ind Ltd 安定化された固型製剤
JPH07206689A (ja) * 1994-01-21 1995-08-08 Barnett Lab Ltd 治療組成物および宿酔の治療のためのこの組成物の使用法
DE19502789A1 (de) * 1995-01-28 1996-08-01 Dirk Krischenowski Arzneimittel
RU2101014C1 (ru) * 1995-09-07 1998-01-10 Акционерное общество "Курский комбинат лекарственных средств" Анальгезирующее, противовоспалительное, жаропонижающее лекарственное средство и способ его получения
US5972916A (en) * 1997-07-14 1999-10-26 Bristol-Myers Squibb Company Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
JP2002012557A (ja) * 2000-06-28 2002-01-15 Lion Corp 内服薬組成物
US20040147606A1 (en) * 2001-05-25 2004-07-29 Yoichi Onuki Medicinal compositions
JP4553552B2 (ja) * 2003-01-08 2010-09-29 日東薬品工業株式会社 生体リズム応用キット

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
US5296241A (en) * 1991-04-03 1994-03-22 Brimberg Barnett J Therapeutic composition and method of using same for treatment of hangover
US6316025B1 (en) * 1997-03-05 2001-11-13 Smithkline Beecham Plc Swallow tablet comprising paracetamol

Also Published As

Publication number Publication date
AR051145A1 (es) 2006-12-20
PT1807068E (pt) 2010-04-19
US20070298096A1 (en) 2007-12-27
EP1807068B1 (en) 2010-03-17
BRPI0520000A2 (pt) 2009-04-07
PE20061125A1 (es) 2006-11-08
AU2005302618A1 (en) 2006-05-11
RU2007119641A (ru) 2008-12-10
RU2398571C2 (ru) 2010-09-10
EP1807068A1 (en) 2007-07-18
ATE460930T1 (de) 2010-04-15
WO2006049978A1 (en) 2006-05-11
MX2007005121A (es) 2007-06-22
CA2583517A1 (en) 2006-05-11
CA2583517C (en) 2013-06-04
CN101048155A (zh) 2007-10-03
PL1807068T3 (pl) 2010-08-31
DE602005020048D1 (de) 2010-04-29
JP2008518914A (ja) 2008-06-05
NO20072255L (no) 2007-07-18

Similar Documents

Publication Publication Date Title
CN100379407C (zh) 生产咀嚼分散片的方法
US5200193A (en) Pharmaceutical sustained release matrix and process
US7741374B1 (en) Methods of use of fenofibric acid
WO1988008299A1 (en) Pharmaceutical sustained release matrix and process
JP2009528329A (ja) 事故的誤用および不法転用を防止するための耐破砕性錠剤
US20130039981A1 (en) Quick Dissolving, Long Acting Zinc Therapeutic Formulations
JPH09500910A (ja) パラセタモール及びドンペリドンのフィルムコーティング錠
WO2014104929A1 (ru) Фармацевтическая композиция для лечения вич-инфекции
CA2583517C (en) Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkaline agent for enhanced absorption
US7993673B2 (en) Swallow tablet comprising paracetamol
WO1996031218A1 (en) Pharmaceutical composition containing sucralfate
JP2003034655A (ja) 速崩壊性固形製剤
AU2014295099B2 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
JPH08333259A (ja) スクラルファート含有製剤組成物
Shyamaladevi et al. Formulation and evaluation of bilayer tablets of Montelukast sodium immediate release and Doxofylline sustained release
KR100697093B1 (ko) 비타민 c 및 감기 치료제를 함유하는 이중정 제형 및 그의제조방법
JP7761480B2 (ja) 固形製剤
EP2848260B1 (en) Novel formulations of thiocolchicoside
KR960006061B1 (ko) 약제학적 서방성 매트릭스 및 제조방법
Kolhe et al. Formulation and evaluation of sustained release bilayer tablets of losartan potassium
CZ20002258A3 (cs) Způsob přípravy stiskem disperzních tablet
HK1062896B (en) Swallow tablet comprising paracetamol
AU2004202902A1 (en) Pharmaceutical composition comprising skim milk powder

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOSITION COMPRISING ACETAMINOPHEN, CAFFEINE AND OPTIONALLY ASPIRIN TOGETHER WITH AN ALKILINE AGENT FOR ENHANCED ABSORPTION

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOSITION COMPRISING ACETAMINOPHEN, CAFFEINE AND OPTIONALLY ASPIRIN TOGETHER WITH AN ALKALINE AGENT FOR ENHANCED ABSORPTION

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GSK CONSUMER HEALTHCARE S.A.

Free format text: FORMER OWNER(S): NOVARTIS AG

HB Alteration of name in register

Owner name: GSK CONSUMER HEALTHCARE SARL

Free format text: FORMER NAME(S): GSK CONSUMER HEALTHCARE S.A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired